Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BuSpar patent appeal

Executive Summary

U.S. appeals court to hear oral arguments on BuSpar patent infringement lawsuit July 12. The court earlier denied Bristol-Myers Squibb's motion for a stay of the D.C. federal court's order to delist a BuSpar metabolite patent from the "Orange Book" and approve generic buspirone (1"The Pink Sheet" April 2, p. 28). Mylan filed suit against Bristol and FDA Nov. 30

You may also be interested in...

Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market

Par Pharmaceutical hopes to capture a portion of the 15 mg buspirone market with the March 28 approval of its 7.5 mg strength of the anxiety drug buspirone, a generic equivalent of Bristol-Myers Squibb's BuSpar. Par has 180-day exclusivity for 7.5 mg buspirone.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts